The aim of this study is to determine the SPF of two test materials ChapStick Moisturizer, Classic Flavor and ChapStick Moisturizer, Strawberry Flavor using the methodology described in the International Standard Test Method. This static methodology also meets the requirements of the Australia/New Zealand standard.

A single-center, randomized, evaluator blind, intra-individual comparison, no treatment and positive controlled clinical study to determine the SPF of two ChapStick sunscreen-containing lip balms as per ISO 24444:2010. For each participant, 4 test sites will have a random assignment number for up to two test materials, control standard, and minimal erythemal dose of unprotected skin (MEDu), with at least 3 of the test sites being utilized for application. All three test sites will be exposed to UV radiation at the expected MED and subsequently evaluated for erythema 16-24 hours after UV exposure.

Inclusion Criteria

• Participant must read and execute an informed consent document (that includes a HIPAA statement) indicating that the participant has been informed of all pertinent aspects of the trial before any assessment is performed;
• Participant must complete a Medical History Form (MHF) prior to their trial initiation;
• Participant must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures;
• Participant must agree not to expose their back to additional sunlight or tanning beds, as either can alter the test results;
• Participant must agree not to apply any topical skin-care product to the test sites during this trial;
• Male or female participants of childbearing potential must agree to use a highly effective method of contraception throughout the trial and for 14 days after the last application of assigned treatment. A participant is of childbearing potential if, in the opinion of the investigator, he/she is biologically capable of having children and is sexually active;
• Female participants of childbearing potential must be willing to comply with urine pregnancy testing requirements prior to initiation of trial testing procedures and as may be required for the duration of the trial;
• Participant must be considered dependable and capable of understanding and following directions;
• Participant must have self-perceived Fitzpatrick skin phototype I, II, or III:

Skin Phototype Sunburn and Tanning History I Always burn easily; never tans II Always burns easily; tans minimally III Burns moderately; tans gradually; and

• Participant must have an Individual Typology Angle value >28 degrees, determined by the Testing Facility by colorimetric methods, within 1 week of trial participation.

Exclusion Criteria

• Participant is in ill health as determined by the Principal Investigator;
• Participant is an employee of the Clinical Division of the investigational site or a member of their immediate family;
• Participant is a GSK CH employee directly involved in the conduct of the trial or a member of their immediate family;
• Female participant is pregnant or intending to become pregnant over the duration of the trial or any female participant of childbearing potential who fails to produce a negative urine pregnancy test;
• Female participant who is lactating (self-reported);
• Participant using medication with photo-sensitizing potential;
• Participant has a history of adverse reactions or hypersensitivity to azo dyes, cosmetics, OTC drugs, or other topical personal care products;
• Participant taking medications other than birth control that could influence the purpose, integrity or outcome of the trial;
• Participant has used topical or systemic steroids, antihistamines, or antibiotics within 7 days of trial initiation or during the trial;
• Participant has used anti-inflammatory medications within 7 days of trial initiation or during the trial, that in the opinion of the PI, could interfere with the trial;
• Participant has used medication suspected of causing photobiological reactions (e.g., tetracyclines, thiazides, etc.), that has not been taken by the participant through a summer season;
• Participant has a dermatological condition;
• Participant has a history of abnormal response to the sun, or a condition such as lupus erythematosus or skin cancer;
• Participant uses tanning beds frequently;
• Participant whose test site was exposed to sunlight within the previous 4 weeks;
• Participant has a sunburn, suntan, uneven skin color, visible skin disease, scarring, or tattoo that would interfere with evaluation of test results; Note: The presence of non-dysplastic nevi, blemishes, or moles will be acceptable if, in the PI's judgment, they will neither compromise the clinical trial, nor jeopardize a participant's safety. A participant with dysplastic nevi should be disqualified.
• Participant has existing sun damage in the test site;
• Participant has excessive hair in the test area and are unwilling to have it clipped; or
• Participant whose test sites have been used for clinical testing in which they were exposed to ultraviolet radiation within the past 2 months.

Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension can be granted, when justified, for up to another 12 months.

Safety Population: all randomized participants who received at least one dose of a study treatment.

From screening until 14 days after last dose administration of trial product (Up to 29 days)

Adverse events (AEs) and Serious Adverse Events (SAEs) were to be collected from time of consent until 14 days after receiving study treatment; SAEs were to be reported within 24 hrs of detection. Diagnosis was to be documented (were known), not individual signs/symptoms. AEs were to be classified by Intensity (mild, moderate, severe); Causality (probable, possible, unlikely); Serious or Non-Serious.